Search Results 191-200 of 17177 for Glucagon

1. Glioma - Doctors and departments - Mayo Clinic

   Gliomas are the most common brain tumors in adults. Learn more about diagnosis and treatment, including innovative research to find new therapies.

2. Manal F. Abdelmalek, M.D. - Mayo Clinic Faculty Profiles

   These new treatments include antimetabolic, anti-inflammatory and antifibrotic therapies such as glucagon-like peptide-1 agonists, pan-peroxisome proliferator- ...

3. Comparison of the Atmo Motility Gas Capsule System to the Reference Standard - Mayo Clinic

   Patients on long-acting glucagon-like peptide (GLP-1). Active implantable devices (e.g., gastric stimulator, pacemaker, defibrillator) [continuous glucose ...

4. Publications - Robert A. Wermers, M.D. - Mayo Clinic

   Glucagon-producing tumors and glucagonoma syndrome. Endocrinologist. 1996 Jul; 6(4):285-93. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The ...

5. A Study to Evaluate Setmelanoitide to Treat Patients with Rare Genetic Disorders of Obesity - Mayo Clinic

   Note: Glucagon-like peptide-1 (GLP-1) receptor agonists may be used up to the dose approved for the treatment of diabetes mellitus (e.g., liraglutide up to ...

6. Study Evaluating The Safety And Efficacy Of Semaglutide, And The Fixed-Dose Combination Of Cilofexor And Firsocostat, Alone And In Combination, In Participants With Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   - History of type 1 diabetes. - Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the period from 90 days prior to the screening visit ...

7. Study To Evaluate The Efficacy And Safety Of Ersodetug In Patients With Inadequately Controlled Hypoglycemia Due To Tumor-Associated Hyperinsulinism - Mayo Clinic

   Initiation of, or significant changes to SOC medical (e.g. diazoxide, SSAs, continuous glucagon, mTOR-Inhibitors, etc.) or supplemental enteral treatments ...

8. Digestive Diseases News - Medical Professionals - Mayo Clinic

   Management of obesity within hepatology clinics. Researchers discuss the role of dietary supplements, glucagon-like peptide 1 receptor agonists, sodium-glucose ...

9. Diabetes - Doctors and departments - Mayo Clinic

   Learn more about the different types of this blood sugar disorder, who's at risk and how each type can be treated.

10. DAYBREAK: Phase 2 Study in Patients With Specific Gene Defects in the MC4R Pathway - Mayo Clinic

    Note: Glucagon-like peptide-1 (GLP-1) receptor agonists may be used up to the dose approved for the treatment of diabetes mellitus (e.g., liraglutide up to ...